IPC
BIIB icon

Independent Portfolio Consultants’s Biogen BIIB Stock Holding History

Independent Portfolio Consultants’s Portfolio BIIB Stock Details BIIB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		$123K Buy
454
+219
+93% +$57.9K 0.05% 381
2017
Q1 		$64K Sell
235
-112
-32% -$31.7K 0.02% 528
2016
Q4 		$98K Buy
347
+59
+20% +$17.5K 0.03% 448
2016
Q3 		$90K Sell
288
-100
-26% -$29.6K 0.03% 460
2016
Q2 		$94K Sell
388
-40
-9% -$10.5K 0.03% 454
2016
Q1 		$111K Buy
428
+40
+10% +$10.6K 0.03% 455
2015
Q4 		$119K Sell
388
-5,126
-93% -$1.47M 0.04% 431
2015
Q3 		$1.61M Sell
5,514
-25
-0.5% -$8.26K 0.35% 94
2015
Q2 		$2.24M Buy
5,539
+123
+2% +$49.4K 0.45% 59
2015
Q1 		$2.29M Buy
5,416
+20
+0.4% +$7.88K 0.47% 63
2014
Q4 		$1.83M Buy
5,396
+3,585
+198% +$1.16M 0.37% 91
2014
Q3 		$599K Buy
1,811
+175
+11% +$57.7K 0.16% 185
2014
Q2 		$516K Buy
+1,636
New +$492K 0.14% 224

Other funds holding BIIB

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Independent Portfolio Consultants's BIIB Position: Q2 2017 in Review

Independent Portfolio Consultants increased its Biogen (BIIB) stake by 93% in Q2 2017, buying an estimated $57.9K and bringing the position to 454 shares worth $123K. The position accounts for 0.05% of the portfolio, ranked #381.

Independent Portfolio Consultants first reported a position in BIIB in Q2 2014 and has held it in 13 quarters since. The position peaked at $2.29M in Q1 2015. 992 funds tracked by Wall St. Rank hold BIIB as of Q2 2017.

  • Independent Portfolio Consultants held 454 shares of Biogen worth $123K as of Q2 2017.
  • Independent Portfolio Consultants bought 219 Biogen shares in Q2 2017, an estimated $57.9K.
  • Biogen made up 0.05% of Independent Portfolio Consultants's portfolio in Q2 2017, its #381 holding.
  • Independent Portfolio Consultants first reported a position in Biogen in Q2 2014 and has held it in 13 quarters since.
  • Independent Portfolio Consultants's Biogen position peaked at $2.29M in Q1 2015.
  • 992 funds tracked by Wall St. Rank held Biogen as of Q2 2017.

Based on Independent Portfolio Consultants's 13F filing for Q2 2017, filed 6 Jul 2017.